Please ensure Javascript is enabled for purposes of website accessibility

Why Zomedica Stock Jumped Today

By Joe Tenebruso - Jan 19, 2021 at 3:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are intrigued by the popular penny stock's new razor and blade strategy.

What happened

Shares of Zomedica (ZOM -0.90%) climbed on Tuesday, following the publication of its CEO's letter to shareholders. As of 2:50 p.m. EST, the veterinary health company's stock price was up 12% after rising as much as 23% earlier in the day. 

So what 

CEO Robert Cohen said Zomedica bolstered its cash reserves by over $40 million, as investors chose to exercise their warrants following its recent stock price gains. In total, Zomedica now has more than $90 million in cash on its balance sheet, which Cohen said would be enough to fund its operating costs through 2023, at which point he expects the company to be generating positive cash flow.

A person is pointing to an upwardly sloping digital stock chart.

Zomedica's stock popped on Tuesday. Image source: Getty Images.

Additionally, Cohen confirmed that the upcoming commercial launch of Zomedica's Truforma point-of-care diagnostic platform remains on track for March 30. Cohen touted the potential for Zomedica to implement a "razor and blades" strategy for Truforma, which could allow the company to enjoy a long-term stream of profits from the sale of assays, in addition to the upfront sales of its diagnostic systems.

Now what 

Zomedica's recent stock price gains were reportedly aided by a scheme in which someone paid Carole Baskin, star of the popular Netflix show Tiger King, to speak positively about Zomedica in a video posted on social media. Yet, at least for today, investors appear to be overlooking these concerns -- instead choosing to focus more on the long-term profit potential of Truforma.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
$0.22 (-0.90%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.